Tempest Therapeutics (TPST) Total Current Liabilities (2011 - 2026)

Tempest Therapeutics has reported Total Current Liabilities for 15 years, with the latest figure at $3.3 million in Q4 2025.

• Quarterly Total Current Liabilities fell 76.69% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (down 76.69% YoY) and the FY2025 annual result came in at $3.3 million, down 76.69% from the prior year.
• Total Current Liabilities declined to $3.3 million in Q4 2025 per TPST's latest filing, from $3.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $24.1 million in Q3 2022 and troughed at $3.3 million in Q4 2025.
• A 5-year average of $12.2 million and a median of $10.2 million in 2021 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2021 and 2025: Total Current Liabilities surged 521.54% in 2021, then sank 76.69% in 2025.
• Over 5 years, Total Current Liabilities stood at $20.0 million in 2021, then tumbled by 63.66% to $7.3 million in 2022, then grew by 29.33% to $9.4 million in 2023, then surged by 51.1% to $14.2 million in 2024, then tumbled by 76.69% to $3.3 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $3.3 million, $3.5 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.